Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux 1.5 mg for VTE Prevention in Renal Insufficiency
NCT00927602Phase 4Terminated
- Sponsor
- University of Insubria
- Start
- Apr 2009
- Primary completion
- Dec 2011
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 4 trial of fondaparinux in venous thromboembolism (VTE), sponsored by University of Insubria. Started Apr 2009; status: terminated.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00927602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00927602.